Risk of cancer in relatives of patients with myelodysplastic neoplasia and acute leukemias
Menée à l'aide de données de registres danois portant sur 8 386 patients atteints d'une néoplasie myélodysplasique, d'une leucémie myéloïde aiguë ou d'une leucémie lymphoblastique aiguë, cette étude analyse le risque, pour leurs parents au 1er ou 2nd degré, de développer ces maladies
Background: The risk of cancer among relatives of patients with either myelodysplastic neoplasia (MDS), acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) has not been thoroughly examined. Methods: We linked the Danish Civil Registration System with the Danish Cancer Registry, the Danish National Acute Leukemia Registry, and the Danish Myelodysplastic Syndrome Database to estimate the relative risk of cancer among relatives of patients with MDS/AML/ALL. We used standardized incidence ratios (SIRs), i.e., the ratio of observed to expected number of cancers among the relatives as a measure of relative risk. Results: We identified 13010 first-degree (FDR) and 22051 second‐degree (SDR) relatives of 8386 patients with MDS/ALL/AML. Disregarding basal cell carcinoma (BCC), the relative risk for cancer overall was increased in both FDR (SIR=1.3; 95% confidence interval (CI) 1.1–1.4) and SDR (SIR=1.5; 95% CI 1.2–1.8). SIRs among FDRs were statistically significantly increased for malignant melanoma, BCC and for the combined groups of cancers of the male genital organs, urinary tract, and MDS/AML/ALL. Among SDRs, SIRs were statistically significantly increased for malignant melanoma, BCC, and cancers in the digestive organs and peritoneum. Conclusions: We observed an increased risk of cancer among FDR and SDR of patients with MDS/AML/ALL.
Cancer Epidemiology 2024